EGFR and non-small cell lung carcinoma: However, recent studies have indicated that the clinical outcomes of non-small-cell lung cancer patients with EGFR mutations are promising and that patients with different EGFR mutations may experience different outcomes of ICI therapy despite their generally low response to ICIs (23, 24).